Summit Therapeutics hits possible snag on lung cancer drug seen as blockbuster
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Readout Newsletter: FDA, Paxil, chikungunya, GSK
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Viking Therapeutics oral weight loss drug hits mark in mid-stage trial
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and…
Ultrasound could deliver drugs with fewer side effects
After testing different types and concentrations of sugars, the researchers found that 5% sucrose added to the liquid…
New Novartis ESC data highlights strength of cardiovascular portfolio
PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol…
Eli Lilly’s much-anticipated obesity pill falls short of Wegovy
Eli Lilly’s investigational obesity pill led to less weight loss in a late-stage trial than the reductions seen…
Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Sarepta Therapeutics’ Duchenne therapy crisis has a clear lesson
In a matter of a few days last week, Sarepta Therapeutics announced major layoffs, acknowledged the death of…
Patient dies in Sarepta gene therapy trial, adding to safety concerns
A 51-year-old man died last month after receiving an experimental gene therapy developed by Sarepta Therapeutics for an…